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Abstract
Commonly used methods for site-directed DNA mutagenesis require copying the entire tar-
get plasmid. These methods allow relatively easy modification of DNA sequences in small
plasmids but become less efficient and faithful for large plasmids, necessitating full
sequence verification. Introduction of mutations in larger plasmids requires subcloning, a
slow and labor-intensive process, especially for multiple mutations. We have developed an
efficient DNA mutagenesis technique, UnRestricted Mutagenesis and Cloning (URMAC)
that replaces subcloning steps with quick biochemical reactions. URMAC does not suffer
from plasmid size constraints and allows simultaneous introduction of multiple mutations.
URMAC involves manipulation of only the mutagenesis target site(s), not the entire plasmid
being mutagenized, therefore only partial sequence verification is required. Basic URMAC
requires two PCR reactions, each followed by a ligation reaction to circularize the product,
with an optional third enrichment PCR step followed by a traditional cloning step that
requires two restriction sites. Here, we demonstrate URMAC’s speed, accuracy, and effi-
ciency through several examples, creating insertions, deletions or substitutions in plasmids
ranging from 2.6 kb to 17 kb without subcloning.
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Introduction
A number of DNA modification techniques involve rapid and efficient site-directed DNA muta-
genesis (SDM) developed in the 1990’s, soon after the invention of polymerase chain reaction
(PCR) [1]. Most SDM techniques make use of one version or another of inverse PCR mutagene-
sis. Inverse PCR was developed by Hemsley et al. [2] and later improved by the use of a proof-
reading DNA polymerase, such as Vent [3], and an enzymatic step to remove background tem-
plate [4]. Another fast mutagenesis method developed by Papworth et al. [5] uses a primer exten-
sion design to copy the plasmid, generating staggered nicks that are repaired by bacteria after
transformation. These and other SDM methods have been commercialized in DNA mutagenesis
kits such as ExCite and QuikChange (Stratagene, La Jolla, CA), and Phusion Site-Directed Muta-
genesis (New England BioLabs, Ipswich, MA). Because these techniques rely on copying the
entire DNA plasmid with primers containing the desired mutation, they generally work best for
plasmids under 3.1 kb in size [6]. This approach has inherent limitations including the difficulty
of copying large plasmids, an increased chance of encountering too-high or too-low GC contents
that slow or stop PCR reactions, and the introduction of unwanted mutations in the plasmid due
to polymerase errors. Introducing a mutation in plasmids larger than 8 kb usually requires sub-
cloning a section of the plasmid containing the site of mutagenesis into smaller cloning vectors
to make the SDM possible. Subcloning is an inherently slow process involving restriction
enzyme digestion, ligation, transformation, colony formation and selection, DNA isolation,
sequence verification, and excision of the mutated DNA sequence from the subclone and its
insertion into the original plasmid. All but the final insertion step are avoided in URMAC.
URMAC employs a minimalistic approach in which PCR reactions are performed on the
smallest possible portion of a large plasmid that contains the mutagenic target site flanked by
unique restriction sites. This approach significantly improves the rate of PCR success and the
quality of the product. In this study, we provide several examples of the applicability of
URMAC for deletion, insertion, or substitution of DNA sequences in plasmids ranging in size
from 2.6 kb to 17 kb.
Results
General description of the URMAC method
URMAC relies on the simple ability of DNA ligation to turn a linear PCR product generated
from a plasmid template into a circular DNA that can be opened at a second site by amplifica-
tion with primers containing the desired mutation(s), circularized by ligation again, and
amplified with the original primers to reproduce the original DNA containing the desired
mutation(s). The same reaction steps can be used to insert, delete, or substitute any number of
DNA nucleotides. Two sets of primers are used in URMAC, the Starter Primers and the Opener
(Mutagenic) Primers. These primers are 50 phosphorylated so that they can participate in the
subsequent ligation step. The Starter Primers are first used to amplify the Modification Target
sequence and again for the final enrichment PCR step. The Opener Primers are used to intro-
duce the mutation of interest. The steps involved in URMAC are illustrated in Fig 1 and
described below.
PCR #1. The Modification Target, a small portion of the plasmid containing the sequence
to be modified, is selected for amplification by PCR. The positions of the Starter Primers (SP1
and SP2) are chosen such that the amplified Starter DNA includes the closest, but at least 150
bp apart, unique restriction sites (X and Y) in the plasmid flanking the site to be modified.
These restriction sites will be used in the final step for insertion of the Modified DNA into the
parental plasmid.
URMAC: DNA cloning and mutagenesis
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Fig 1. The URMAC method. This illustration depicts a hypothetical insertion within a Modification Target
(black lines) in the Original DNA plasmid. PCR #1 generates the Starter DNA copy of the Modification Target
including the flanking unique restriction sites, X and Y. It is produced by a thermostable DNA polymerase
using the Starter Primers, SP1 and SP2 (black arrows). The Starter DNA is circularized with T4 DNA ligase to
generate the Closed Starter DNA. The Closed Circular DNA serves as the template for PCR #2, directed by
the Opener Primers, OP1 and OP2, to produce the mutated Intermediate DNA. In this illustration, OP1 has
incorporated an insertion mutation by having the sequence of interest (depicted as an open box) attached to
URMAC: DNA cloning and mutagenesis
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Ligation #1. The Starter DNA is circularized in a self-ligation reaction to generate the
Closed Starter DNA.
PCR #2. The Closed Starter DNA is opened at the site of the desired mutation by inverse
PCR using the Opener (Mutagenic) Primers (OP1 and OP2) facing opposite directions from
the opening site to generate the linear Intermediate DNA containing the mutation(s) at its ter-
mini. Sequences can be: deleted at the site of opening by moving the primers apart; inserted by
adding nucleotides to the 50 terminus of one or both of the primers; or mutated by changing
one or more nucleotides in one or both primers. Any combination of deletion, insertion or
substitution can be designed into the Opener Primers.
Ligation #2. The Intermediate DNA is circularized by self-ligation to generate the Closed
Intermediate DNA. The desired mutation is now in place and the fragment can be excised and
ligated into the original plasmid.
Optional enrichment PCR Step. The Closed Intermediate DNA can be amplified by the
same pair of Starter Primers that were used to amplify the Starter DNA in the first step (SP1
and SP2) to generate the Linear Modified DNA. This PCR step increases the number of DNA
molecules with desired modifications for ligation into the original plasmid.
Restriction digestion and insertion. Both the Linear Modified DNA and the original plas-
mid are digested with the unique restriction enzymes identified in the first step (X and Y in Fig
1), and purified. The final DNA with the modifications sequence is ligated into the parental
plasmid to produce the final product containing the desired mutation(s). By the end of the
final PCR enrichment step, the amount of the Original DNA carryover from the first PCR
reaction step is insignificant due dilution factors. Optionally, the addition of 1unit DpnI
restriction enzyme to the first ligation step completely removes any potential carryover of the
full Original DNA plasmid during the URMAC procedures. The success rate of obtaining the
correct clones after the final cloning step is normally over 95%.
Validation of the method: Introducing insertion, deletion and substitution
mutations
For validation of the URMAC method, we used pUC18, a widely available plasmid, as a target
to test URMAC by either removing or adding a restriction site. We performed all three differ-
ent types of DNA mutagenesis using the same Closed Starter DNA from the first PCR and liga-
tion reactions as a template (Fig 2A).
We inserted the recognition sequence of a MluI restriction enzyme next to that of the native
NdeI, substituted the NdeI recognition sequence with that of the MluI (that is simultaneous
deletion of NdeI and insertion of MluI recognition sequences), or deleted the NdeI recognition
sequence, all by altering the 50 ends of the OP1 and OP2 primers or positioning them appropri-
ately (Fig 2b, and Table 1).
Since the Starter DNA was only 532 bp long (Fig 2A), roughly 20% of the full plasmid size,
it was amplified in 60 minutes, more quickly than the whole plasmid would have been. The
mutagenesis steps followed the basic URMAC steps illustrated in Fig 1.
Successful mutagenesis was verified by restriction analysis (Fig 2c). The PCR-enriched Lin-
ear Modified DNA from each mutagenic reaction was digested with NdeI, which cuts once,
its 50 terminus. The Intermediate DNA is circularized with T4 DNA ligase. The SP1 and SP2 primers are used
in the enrichment PCR step to amplify the Linear Modified DNA. The Linear Modified DNA, and the original
plasmid are digested with the restriction enzymes that cleave at the unique restriction sites, X and Y, and the
appropriate fragments are ligated to produce the Modified Original DNA.
https://doi.org/10.1371/journal.pone.0177788.g001
URMAC: DNA cloning and mutagenesis
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Fig 2. Validation of the URMAC method by insertion (I), substitution (S), or deletion (D) of some restriction sites in
pUC18 plasmid. (A) Illustration of the Modification Target (NdeI restriction site) relative to the flanking restriction sites and
location of the Starter Primers SP1 and SP2. After the first PCR, the Starter DNA migrated as expected, 532 bp on a 1% agarose
gel (photo, arrow at right). A 100 bp DNA size ladder is shown in left lane for comparison. (B) Diagram of the strategy for I, S, or D
using the Closed Starter DNA circularized from the PCR product in (A) as template and the Opener/Mutagenic Primers. The top
photo shows the PCR product, Intermediate DNA, which contained the mutations. The bottom photo shows the Modified DNA
after enrichment PCR step using SP1 and SP2. (C) Validation of URMAC mutagenesis for the three different types of mutations
URMAC: DNA cloning and mutagenesis
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except when the NdeI site was replaced by substitution (S) or removed by deletion (D). MluI
cuts only the inserted (I) or substituted (S) MluI Linear Modified DNA.
URMAC mutagenesis in plasmids with complex GC regions
PCR reactions on GC-rich templates are problematic. Additives such as DMSO, glycerol,
formamide, PEG and other organic compounds [7–10] can help to overcome some of the
problems associated with PCR on GC-rich templates, However GC, complexities remains a
problem that can be avoided by limiting the mutagenesis to smaller regions of the target DNA
rather amplifying the full plasmids. In this experiment, we aimed to introduce substitution
mutations in two expression plasmids, pCG-H (6,669 bp) and pCG-F (6,411 bp), having GC-
rich regions that had failed in previous inverse PCR mutagenesis attempts in our laboratory.
At 40-nucleotide resolution scanning (see methods), the plasmids contained a 79.5% GC
region in pCG-H and 85.4% in pCG-F. We avoided the need to amplify these GC regions
which would have been necessary if we had used inverse PCR mutagenesis, by amplifying and
manipulating only the region of interest by URMAC.
The pCG-H and pCG-F plasmids contain the attachment (H) and fusion (F) glycoproteins
of Edmonston B strain of measles virus (MV) [11]. Together, these two viral glycoproteins
enable the MV virion envelope to attach to and fuse with the target cell membrane to initiate
infection. When the H and F proteins are co-expressed on the cell surface during infection or
following transfection, they interact with cellular receptors on neighboring cells causing cell-
cell fusion resulting in the formation of syncytia. Based on this fusion phenomenon, we tested
the functional ability of mutant H and/or F with a modified integrin-binding Leu-Asp-Val
(LDV) motif to induce syncytia in two cell lines, Vero and BKH-21. In Vero cells, our positive
control, the MV glycoproteins can use the cell surface CD46 molecule as a receptor to initiate
fusion independent of interaction with the LDV motif. However, BHK-21 hamster cells do not
express CD46, but they express the integrins that interact with the LDV motifs on viral H and
F proteins. To determine whether or not the LDV motif in either the H or F glycoprotein is
critical for fusion, we used URMAC to replace the central Asp (D) with the similar amino acid,
Glu (E), to create an H protein variant, D79E, and an F protein variant, D461E.
To perform this mutagenesis, we designed a pair of Starter Primers (Table 1) to amplify the
region encoding the LDV motif in the F gene in pCG-F, and another pair for the H gene in
pCG-H, including appropriate native restriction sites in the amplicons. The substitution reac-
tion steps were performed as described above for pUC18. After generating the final plasmids
that carry the desired modifications, the DNA of 5 clones for both mutants was sequenced at
the mutation sites. All 10 sequenced clones contained the correct mutations. The biological
significance of the mutations was investigated by performing a fusion assay(data not shown).
In addition to the D-to-E mutations in pCG-H and pCG-F, we generated several other
mutations in the LDV motif of both the F and H proteins using a single Opener Primer in con-
junction with a series of mutagenic Opener Primers on the same Closed Starter DNA template.
Fig 3B illustrates this approach that generated four different mutations, L78A, D79A, D79E,
and V80A, using a single common Opener Primer (OP2) paired with a series of mutagenic
Opener Primers (OP1). This approach easily enables any number of mutations to be built into
by restriction analysis. Fig 2C shows bands of expected DNA fragment size after digestion with respective restriction enzymes. In
the control Starter PCR lane, only DNA treated with NdeI enzyme, cut the DNA into two fragments of 382 & 150 bp. Untreated
DNA or DNA treated with MluI remained at the full size of 532 bp. In the Insertion lane, both NdeI and MluI cut the DNA at the
expected sizes of 382 & 150 for NdeI and 383 & 149 for MluI. In the Substitution lane, only MluI cut the DNA producing the
expected 383 & 149 bp bands. In the Deletion lane, none of the enzymes cut the DNA, leaving the bands at their original Modified
DNA size.
https://doi.org/10.1371/journal.pone.0177788.g002
URMAC: DNA cloning and mutagenesis
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a motif or region by changing the sequence of only one of the primers used in this step. Intro-
ducing mutations in the pCG-H and pCG-F took one day for the URMAC biochemical reac-
tions and an additional 3 days to clone the Linear Modified DNA into the original plasmids.
URMAC did not require extensive optimization since the PCR was used to copy only 10% of
Table 1. List of primers.
Primer Name Sequence
Primer sets for pUC18 deletion, insertion, and substitution
SP1 ACACATGCAGCTCCCGGAGA
SP2 CTCACTCATTAGGCACCCCAGG
OP1D> CGGTGTGAAATACCGCACAGAT
OP2D< GTGCACTCTCAGTACAATCTGC
OP1S> CGTCGGTGTGAAATACCGCACA
OP2S< CGTGTGCACTCTCAGTACAATC
OP1I> CATATGCGGTGTGAAATACCGCAC
OP2I< ACGCGTGTGCACTCTCAGTACAAT
H glycoprotein mutagenic primers for the LDV motif
SP1-H> TTTGTCATGTTTCTGAGCTTG
SP2-H< CAAGTGAGATCTCTGAAGTCG
Common ReverseprimerOP2-H< ATTGGTGCTGAGGCTTTTATG
Leu to Ala H-OP1-LΔA> GCAGATGTAACTAACTCAATC
Asp to Ala H-OP1-DΔA> CTAGCTGTAACTAACTCAATCGA
Asp to Glu H-OP1-DΔE> CTAGAAGTAACTAACTCAATCGAG
Val to Ala H-OP1-VΔA> CTAGATGCAACTAACTCAATCGAGCA
F Glycoprotein mutagenic primers for the LDV motif
SP1-F> CCAAGTATGTCGCAACCCAAG
SP2-F< ACTCCTCAATATCTGGTCCGA
ReversePrimer OP2-F< CCTCTCCAATGATATGGGAGG
Leu to Ala F-OP1-LΔA> GCGGACGTAGGGACAAATCT
Asp to Ala F-OP1-DΔA> TTGGCCGTAGGGACAAATCTGGG
Asp to Glu F-OP1-DΔE> TTGGAGGTAGGGACAAATCTGGGG
Val to Ala F-OP1-VΔA> TTGGACGCAGGGACAAATCTGGGGAA
Primer set for substitution mutation A1043G in the MD cDNA
SP1-MD> ATAGTCATAGGCCAGACC
SP2-MD< CCACAGTAATCTGCCTCTTC
OP1-MD> CTATTCTCAACAGATCGCGGT
OP2-MD< CAGTCTAGCACAGGGATATGA
Primer set for deletion of the M2-1 or M2-2 ORF from the RSV replicon cDNA
SP1-RSV> ACTTGTATCGTCGCCATCGG
SP2-RSV< AGAAACGTAGTCCTGATAAC
OP1-RSV< ATTTGCCCCAGTTTTCATTTTTAC
OP2-RSV> CAAATGACCATGCCAAAAATAATGATAC
OP3-RSV< GTCAGGTAGTATCATTATTTTTG
OP4-RSV> CACCACATCGTTACATTATTAATTC
* Primers in this table are modified by the addition of a phosphate group at their 50 ends. Abbreviations: SP, Starter Primer; OP, Opener Primer; I, insertion;
D, deletion; S, substitution; MD, muscular dystrophy; and RSV, respiratory syncytial virus. The capital H in primer names indicates the primer was designed
for mutagenesis in the measles H glycoprotein DNA sequence in pCG-H plasmid and the F in the fusion glycoprotein DNA sequence in the pCG-F plasmid.
The “>” sign = forward and the “<” sign = reverse primer orientation. Underline: native NdeI recognition sequence. Bold, italics: inserted MluI recognition
sequence. Bold and underlined G in OP1-MD reflects a substitution of A to G.
https://doi.org/10.1371/journal.pone.0177788.t001
URMAC: DNA cloning and mutagenesis
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the plasmid in this case avoiding regions of high GC content. We conclude from this experi-
ment that URMAC can be easily used to introduce mutations in 6–7 kb plasmids containing
regions of widely disparate GC content without resorting to conventional subcloning.
Introduction of a point mutation into the 11 kb dystrophin cDNA by
URMAC
Large plasmids present a challenge for PCR-based mutagenesis methods that require amplify-
ing the full sequence while preventing the introduction of unwanted mutations caused by PCR
infidelity. A fragment of the cDNA can be subcloned into a smaller plasmid, mutagenized and
the fragment returned to the original plasmid, but this process is time consuming.
As an example, the cDNA for muscle dystrophin open reading frame is approximately 11
kb [12]. Mutations in dystrophin are associated with a spectrum of clinical phenotypes,
grouped as “dystrophinopathies” including Duchenne muscular dystrophy (DMD), Becker
muscular dystrophy (BMD), and X-linked dilated cardiomyopathy (XLDCM) [13, 14]. DMD
and BMD are characterized by progressive skeletal muscle degeneration and development of
cardiac disease leading to premature death, with DMD having an earlier childhood onset and
a more severe disease progression than BMD. By contrast, XLDCM patients typically only
Fig 3. Pairing a variety of mutagenic Opener Primers (OP1 series) with a single common primer (OP2) was used to generate
four different variants of the MV H glycoprotein. The OP1 series (Table 1) were used in separate PCR reactions with the same OP2
primer on the same Closed Starter DNA to simultaneously generate four different mutant Linear Intermediate DNA PCR products
containing indicated mutations (lower panel). These mutant PCR products were circularized, amplified with the /Starter Primers/ and
cloned into the Original DNA plasmid generating four different pCG-H plasmids, each expresses a different MV H glycoprotein variant.
https://doi.org/10.1371/journal.pone.0177788.g003
URMAC: DNA cloning and mutagenesis
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develop severe cardiac disease and as a result, are treated with a cardiac transplant. To study
the differential effects of mutations on the function of dystrophin in striated muscles, it is criti-
cal to ensure that only the desired mutation is introduced during the mutagenesis process.
Given the 11kb size of the cDNA alone, introduction of mutations in dystrophin would require
subcloning.
To determine whether URMAC could be a viable and fast substitute for subcloning in such
a large plasmid, we sought to introduce a point mutation in the full length dystrophin cDNA.
We chose the A1043G missense mutation in exon 9 that results in a Threonine to Alanine sub-
stitution at amino acid 279. This substitution is found in one family with very early onset and
severe XLDCM [15, 16].
We started with a commercially available 13.8 kb Gateway entry vector plasmid containing
the full length human muscle dystrophin cDNA (11,061 bp). As shown in Fig 4a, the URMAC
approach was used on an isolated 1,629 bp region containing exon 9 and two flanking unique
restriction enzyme sites (NsiI and SphI).
This allowed us to modify this short fragment without copying the rest of the cDNA or plas-
mid sequences. The region to be altered was amplified using the Starter Primers (Table 1) to
produce the Starter DNA. The Starter DNA was ligated and amplified with the mutagenic
Opener Primers (Table 1) containing the A to G mutant sequence to generate the Intermediate
DNA. Following circularization, the Starter Primer pair was used to generate the Linear Modi-
fied DNA. This entire procedure was completed in 6 hours. The Linear Modified DNA was
digested with NsiI and SphI and inserted into the original plasmid. Sequencing of the cDNA
region that was isolated for URMAC confirmed the A1043G point mutation (Fig 4B), and
sequencing of the entire cDNA, confirmed that this was the only mutation.
Despite the size of the human dystrophin cDNA, introducing a point mutation by URMAC
was simple and fast, requiring minimal effort and materials. The entire process from beginning
to full sequencing of the final mutagenized plasmid was completed in less than one week.
Deletion of open reading frames from a large plasmid containing multiple
genes
In this example, we used URMAC to delete two open reading frames (ORF) from a 17 kb plas-
mid containing the human respiratory syncytial virus (RSV) genome from which its three gly-
coprotein genes had already been deleted and two foreign marker genes inserted by
conventional subcloning methods. Transcription of this plasmid in mammalian cells, along
with the expression of the 4 viral proteins involved in genome replication and mRNA tran-
scription, initiates continuous intracellular replication of this RNA virus replicon [17, 18]. The
aim was to determine whether two of the RSV genes, M2-1 and M2-2, are required for RSV
replication and survival.
At 17 kb, this plasmid was too large to be modified by current methods without subcloning.
We used the URMAC method to individually delete the M2-1, M2-2 or both ORFs from the
replicon cDNA by the scheme shown in Fig 5a.
The Starter Primers were designed to flank the M2 gene and the unique XhoI and AarI sites,
and used to produce a 2.7 kb Starter DNA. Following ligation, the Closed Starter DNA was sub-
jected to the second round of amplification using various pairings of the 4 Opener Primers to
generate Linear Intermediate DNAs with the deletions.
Following ligation, each of the three Closed Intermediate DNAs were enriched by a third
PCR using the Starter Primers. The three resulting Linear Modified DNAs were digested with
XhoI and AarI and inserted into the parental plasmid to generate three RSV replicon plasmids
with: M2-1 ORF deleted (ΔM2-1), M2-2 ORF deleted (ΔM2-2), and both ORFs deleted (ΔM2).
URMAC: DNA cloning and mutagenesis
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Deletions were confirmed by the size of the PCR products amplified by the Starter Primers (Fig
5b) and by sequencing the DNA region between the XhoI and AarI restriction sites. URMAC
enabled the rapid deletion M2-1 and M2-2 from this large plasmid, allowing a quick test of the
importance of the M2 genes for RSV genome replication and survival.
Discussion
The URMAC technique provides several advantages over other existing technologies for DNA
mutagenesis. In URMAC, mutagenesis is minimalistic: only the smallest region targeted for
mutagenesis in a given DNA sequence/plasmid is subjected to molecular manipulation. For
example, in our MV H and F gene mutagenesis experiments, URMAC was applied to only 287
bp and 512 bp of the pCG-H and pCG-F plasmids instead of the entire 6,669 bp and 6,411 bp,
leaving more than 95% of the plasmids untouched by the DNA polymerase. This lends several
benefits to the URMAC technology: 1) PCR reactions have a higher success rate with small
fragments rather than with full-length plasmids; 2) URMAC has a lower chance of introducing
polymerase errors than the primer extension SDM method (QuikChange) and inverse PCR
Fig 4. Single base pair substitution in dystrophin using URMAC. (A) Schematic representation of the relative sizes of the
original plasmid, the full length human dystrophin cDNA within the plasmid and the final fragment that was isolated for point
mutagenesis using the URMAC method. The rest of the dystrophin cDNA sequence was left intact. (B) Sequencing of the
mutagenized region after re-ligation into the dystrophin cDNA at the correct position. The desired single A to G substitution was
the only mutation found by sequencing the entire dystrophin cDNA.
https://doi.org/10.1371/journal.pone.0177788.g004
URMAC: DNA cloning and mutagenesis
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Fig 5. Deletion of the M2-1 or M2-2 ORF, or both from the RSV replicon plasmid. (A) The URMAC scheme used to
generate the three M2 deletion replicon constructs. (B) PCR confirmation of the final replicon constructs. Primers SP1 and
SP2 were used to amplify the region encompassing all of the desired mutations, by PCR. The targeted deletion region of
each replicon plasmid is listed above each lane (ΔM2-1, ΔM2-2, ΔM2). Predicted PCR product sizes for the deletions were
2.1 kb, 2.4 kb, and 1.8 kb, respectively. The comparable product from the parental replicon plasmid, MP312, containing the
entire M2 gene was 2.6 kb. MW indicates molecular weight markers.
https://doi.org/10.1371/journal.pone.0177788.g005
URMAC: DNA cloning and mutagenesis
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because the fragment being amplified is much smaller; 3) regions of any plasmid that are not a
direct target for mutagenesis remain untouched by DNA polymerase and therefore do not
require sequence verification, a critical consideration when dealing with plasmids containing a
very large gene such as the dystrophin gene, or multiple genes such as the RSV replicon; 4)
URMAC is very fast compared to conventional SDM requiring subcloning, with an average of
a single day to complete URMAC and an additional 3 days to clone the final product into the
original plasmid, compared to at least 3–4 weeks required for subcloning; 5) URMAC can dra-
matically reduce the challenge of high GC-containing plasmids by avoiding PCR amplification
of those parts of a plasmid; and 6) URMAC requires less labor and materials and therefore
costs less than subcloning.
Furthermore, URMAC is versatile for handling any combination of insertions, deletions or
substitutions. While QuikChange is fast in creating a single or double nucleotide mutation in a
small plasmid, larger or multiple changes are more difficult. URMAC does not suffer from this
limitation since the mutation is inserted at the 50 end of a short primer rather than in the mid-
dle of longer mutagenic primers. In this way, URMAC is similar to the inverse PCR tech-
niques, yet it does not suffer from the size limitation of inverse PCR. Like URMAC, another
method, called splice overlap mutagenesis (SOM) [19], requires the availability of restriction
sites, but SOM primers must be complementary to the target DNA in both orientations at the
joining ends of the two PCR products, limiting control over the primer design and their effec-
tiveness. Since URMAC does not require the joining of PCR products, URMAC does not suf-
fer from this limitation. When individual mutations are required in adjacent regions of the
plasmid to generate multiple separate mutants, the Closed Starter DNA can serve as a template
for all of the mutations by designing different Opener Primers. The Closed Intermediate DNA
can be recycled as Closed Starter DNA, once for each mutation.
Although URMAC mutagenesis is not affected by the size of the original plasmid because
the actual mutagenesis is performed on only a small region, inserting the final PCR product
into the original plasmid does depend on the availability of unique restriction sites. In plasmids
of 30 kb or larger, the availability of such restriction sites becomes limited. In this case, an
alternative recombineering strategy [20] could be incorporated into the URMAC technique to
facilitate the insertion of the mutated sequences back into very large plasmids irrespective of
the availability of restriction sites.
In summary, compared to conventional site-directed mutagenesis methods, including
those that require subcloning, the URMAC technology is versatile, simple, efficient and cost-
effective. It is particularly useful for large plasmids but also works well for small plasmids.
Methods
Mutations in pUC18 accession number L09136
All PCRs were carried out using 100 pg pUC18 as a template and 75 pmol of Starter Primers 1
and 2 (Table 1) in a total volume of 25 μl containing 1 unit Pfu DNA polymerase (Agilent
Technologies, Santa Clara, CA) and the appropriate amplification buffer unless otherwise
stated. PCRs were performed using the following thermocycling conditions: denaturation at
94˚C for 2 min followed by 25 cycles of 94˚C, 20 sec; 60˚C, 30 sec; 68˚C, 1 min, and a final
extension at 68˚C for 5 min. DNA electrophoresis on 1% agarose gel confirmed that the Starter
DNA had been produced (Fig 2A). 2.5 μl of the Starter DNA, estimated at 50–100 ng, was cir-
cularized by self-ligation using 1 unit of T4 DNA ligase in a total reaction mix of 20 μl for 10
min at 20˚C. 1 μl of a 1:200 dilution of the Closed Starter DNA product in deionized H2O was
used as a template for the second round of PCR, but this time various pairs of Opener Primers
(Table 1) were used. 2.5 μl of these products were self-ligated with T4 DNA ligase as above and
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1 μl of a 1:200 dilution of the Closed Intermediate DNA product was used as a template for the
final PCR reaction to create the Linear Modified DNA. Successful mutagenesis was confirmed
by restriction analysis using NdeI and MluI restriction enzymes (New England Biolabs, Ips-
wich, MA): 2 μl of Linear Modified DNA for each mutation type was incubated with or without
5 units of restriction enzymes for 30 min at 37˚C. 5 μl of each reaction was resolved by electro-
phoresis on a 1% agarose gel. For cloning the modified DNA into the parental DNA, a stan-
dard protocol was used, briefly, both the fragment and the plasmid were digested with 5 units
of PfoI and EcoRI separately. The appropriate fragments were gel-purified using QIAquick Gel
Extraction kit (Qiagen MiniPrep Kit (Qiagen, Hilden, Germany) and eluted with 30 μl TE
buffer. The DNA was measured by Nanodrop™ 2000C instrument (Thermofisher, Wilming-
ton, DE). 15 fmol of plasmid’s backbone was mixed with 45 fmol insert and incubated with T4
DNA ligase and ligation buffer for a total of 20 μl and the reaction was incubated for 1 hr at
16˚C. The reaction was terminated by incubation at 65˚C for 10 minutes. The reaction was
then diluted 5-fold in pure H2O. 5 μl of diluted reaction was used to transform 50 μl DB3.1 E.
coli chemically competent cells (Invitrogen). For sequence screening of final clones, the same
Starter Primers were used for sequencing the full 500 nucleotide span of the modification
target.
Introducing substitution mutations into the H and F glycoproteins of MV
Starter Primers (Table 1) were used to amplify the DNA sequences that include the LVD motifs
(50-CTA GAT GTA-30 and 50-TTG GAC GTA-30) in the pCG-H and pCG-F [11] plasmids
containing the H and F glycoprotein genes, respectively, and the flanking, unique restriction
sites (NheI and BspEI for the H gene and KpnI and XcmI for the F gene). The Starter DNA for
H was 287 bp and for F was 512 bp. The pCG-H and pCG-F plasmid sizes were 6,669 bp and
6,411 bp, respectively. PCR amplifications and ligations were performed as described for the
pUC18 mutagenesis above.
GC region scanning was performed using BioAnnotator module of Vector NTI version 11
(Invitrogen, Carlsbad, CA). Briefly, full DNA sequences of pCG-H or pCG-F plasmids were
loaded into the BioAnnotator program, then subjected to GC% analysis under the Analyze
Selected Molecule tab. The GC% scanning window was left at the default of 40 nucleotide
under the Select Window tab. Percent of GC% contents of each plasmid were noted at the
highest peaks of the histogram.
Mutagenesis of muscular dystrophy gene
A modified Gateway entry vector (pENTR223.1, Clone ID: 40080544) containing the full-
length human muscle dystrophin cDNA (11.061 kb) was obtained from the ORFeome Collab-
oration-OCAB (http://www.orfeomecollaboration.org/html/index.shtml). The sequence is
deposited in NCBI under accession number BC111587. The Pfu DNA Turbo polymerase
(Stratagene) was used for all PCRs. Thermocycling conditions for the Starter Primers (Table 1)
for the first and third PCR were as follows: denaturation at 94˚C for 2 min, followed by 25
cycles of 94˚C, 30 sec; 57.2˚C, 30 sec; and 68˚C, 3 min, followed by a final extension at 68˚C
for 10 min. Thermocycling conditions for the Opener Primers (Table 1) in the second PCR
were as follows: denaturation at 94˚C for 2min followed by 25 cycles of 94˚C, 30 sec; 53.1˚C,
30 sec; and 68˚C, 2 min, followed by a final extension at 68˚C for 10 min. PCR products
(Starter and Intermediate DNA) were re-circularized by ligation with T4 DNA ligase for 15
min at room temperature followed by an optional enzyme inactivation at 65˚C for 10 min.
The final product (Linear Modified DNA) and the parent plasmid were digested with NsiI
and SphI (New England Biolabs) and then ligated overnight at 14˚C.
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The final ligation reaction was diluted 1:5 in distilled water and 5 μl was used to transform
50 μl DB3.1 E. coli chemically competent cells (Invitrogen). Ampicillin resistant colonies were
selected for plasmid isolation using the Qiagen MiniPrep Kit (Qiagen, Hilden, Germany). For-
ward and reverse primers were designed about 250 bp apart using Primer Select (Lasergene-
DNAStar, Madison, WI) to perform a primer walk of the entire original and mutagenized plas-
mids. Plates were sequenced at Boston Children’s Hospital, Boston, MA. Sequencing the entire
cDNA of muscular dystrophy was performed the DNA sequencing facility at Nationwide Chil-
dren’s Hospital, Columbus, OH.
Deletion of two open reading frames from the RSV plasmid
Starter Primers (Table 1), the RSV replicon plasmid MP312, and VENT polymerase (New
England Biolabs, Ipswich, MA) were used to generate the Starter DNA, under the following
thermocycling conditions: denaturation at 94˚C for 2 min, followed by 25 cycles of 94˚C, 20
sec; 53˚C 30 sec; and 72˚C, 3 min, followed by 72˚C for 5.5 min. Following ligation with T4
DNA ligase, Opener Primer pairs (Table 1) and Pfu Turbo polymerase (Stratagene) were used
to generate the three Intermediate DNAs under these conditions: denaturation at 95˚ for 2 min
followed by 25 cycles of 95˚C, 20 sec; 51˚C, 30 sec; and 72˚C, 3 min, followed by 72˚C, 10 min,
and finally 4˚C. The third PCR also used the Starter Primers and Pfu Turbo polymerase under
the thermocycling conditions of the first PCR. Restriction digestion of the parent plasmid and
the Linear Modified DNAs were done using enzymes XhoI (New England Biolabs) and AarI
(Fermentas, Glen Burnie, MD).
Ligations were performed with T4 DNA Ligase (Invitrogen, Carlsbad, CA) overnight at
14˚C. The final ligation reaction was diluted 1:5 in distilled water and 5 μl was used to trans-
form 20 μl of ElectroMax DH10B E. coli cells (Invitrogen). Electroporation was carried out
using BioRad Gene Pulser II (BioRad, Hercules, CA) under the following conditions: 1.8 kV,
25 Faradays and 100 O in 0.1-cm cuvettes cooled on ice then 1 ml SOC media was added and
cells were incubated 1 hour at 37˚C. 200 μl of recovered cells were spread on LB agar plates
supplemented with 10 μg/ml tetracycline and incubated for 48 h at 33˚C. LB agar plates were
prepared by mixing 10g Bacto-tryptone, 5g yeast extract, 10g NaCl and 15g Bacto agar in 1
liter of Nanopure water and autoclaved, then cooled to 50˚C before pouring into perti dishes.
Individual colonies were screened for inclusion of the proper ΔM2 fragment by PCR with
the Starter Primers followed by DNA sequencing to confirm insertion of the correct mutation.
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